

Leukemia

**A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients Aged  $\geq$  60 Years With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy**

**Trial Status**  
Completed

**Trial Runs In**  
4 Countries

**Trial Identifier**  
NCT02670044 2015-003386-28  
GH29914

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

The primary objective for this study is to assess the safety and tolerability as well as preliminary efficacy of venetoclax in combination with cobimetinib, and venetoclax in combination with idasanutlin in patients with relapsed or refractory acute myeloid leukemia (R/R) AML who are not eligible for cytotoxic therapy.

**Hoffmann-La Roche**  
Sponsor

**Phase 1/Phase 2**  
Phase

**NCT02670044 2015-003386-28 GH29914**  
Trial Identifiers

***Eligibility Criteria:***

**Gender**  
All

**Age**  
 $\geq$ 18 Years

**Healthy Volunteers**  
No